# US 2012/0252000 A1 · Real time multipoint assay for optimizing performance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252000 A1
- Document ID: US20120252000A1
- Status: Published application
- Kind: A1
- Application number: 13/436,701
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2008-03-31
- Inventors: Barb Ariel Cohen
- Web page: https://patentgrep.com/patent/US20120252000A1

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/689: {related to pregnancy or the gonads}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2405/04: Phospholipids, i.e. phosphoglycerides
- G01N 2800/367: Infertility, e.g. sperm disorder, ovulatory dysfunction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein are methods of optimizing the performance of a mammalian semen sample with respect to outcomes such as fertility, using a multipoint assay to determine an optimum time point for preparing the semen sample for use in insemination. The multipoint assay is based upon a kinetic model of biomarker expression during sperm capacitation relative to the outcome of interest.

## Claims

### Claim 1

A method of optimizing sperm performance of a semen sample upon insemination of said semen sample, comprising:
i) selecting a marker, wherein expression of the marker in the semen sample changes with time during capacitation;
ii) determining the level or location of expression of the marker in the semen sample at a plurality of time points during incubation of said semen sample before insemination of said semen sample;
iii) determining a timepoint for preparing said semen sample for use in insemination, wherein said timepoint is based upon a calibration of the marker expression displayed by said semen sample in step (ii) to a kinetic model of biomarker expression during sperm capacitation relative to said performance;
iv) preparing at about said timepoint of step (iii) said semen sample for use in insemination;
thereby optimizing said performance of said semen sample upon insemination of said semen sample.

### Claim 2

A method of optimizing sperm performance of a semen sample upon insemination of said semen sample, wherein said semen sample has been exposed to a treatment which modulates the rate of capacitation, comprising:
i) selecting a marker, wherein expression of the marker in the semen sample changes with time during capacitation;
ii) determining the level or location of expression of the marker in the semen sample at a plurality of time points after exposure to said treatment and during incubation of said semen sample before insemination of said semen sample,
iii) determining a timepoint for preparing said semen sample for use in insemination, wherein said timepoint is based upon a calibration of the marker expression displayed by said semen sample in step (ii) to a kinetic model of biomarker expression during sperm capacitation relative to said performance;
iv) preparing at about said timepoint of step (iii) said semen sample for use in insemination;
thereby optimizing said performance of said semen sample upon insemination of said semen sample.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the semen sample is mammalian.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the semen sample is human.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the sperm performance comprises enhanced fertility.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein the sperm performance comprises gender bias.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the sperm performance comprises female gender bias.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein the sperm performance comprises male gender bias.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2, wherein preparing said semen sample for use in insemination comprises freezing said semen sample or vitrification of said semen sample.

### Claim 10 (depends on 9)

The method of claim 9, wherein the sperm performance comprises resistance to freezing when preparing said semen sample for use in insemination.

### Claim 11 (depends on 9)

The method of claim 9, wherein the sperm performance comprises resistance to vitrification when preparing said semen sample for use in insemination.

### Claim 12 (depends on 1, 2)

The method of claim 1 or 2, wherein the marker and the biomarker are identical.

### Claim 13 (depends on 1, 2)

The method of claim 1 or 2, wherein the marker and/or the biomarker is an Fc receptor.

### Claim 14 (depends on 1, 2)

The method of claim 1 or 2, further comprising more than one marker.

### Claim 15 (depends on 1, 2)

The method of claim 1 or 2, wherein the kinetic model of biomarker expression during sperm capacitation comprises more than one biomarker.

### Claim 16 (depends on 1, 2)

The method of claim 1 or 2, wherein the kinetic model of biomarker expression during sperm capacitation comprises a biomarker which binds to the constant region of an antibody.

### Claim 17 (depends on 1, 2)

The method of claim 1 or 2, wherein the semen sample is not treated by fixation.

### Claim 18 (depends on 1, 2)

The method of claim 1 or 2, wherein the semen sample is not exposed to treatment to increase permeability of the membrane.

### Claim 19 (depends on 1, 2)

The method of claim 1 or 2, wherein the first of said plurality of time points is obtained immediately after collection of said semen sample.

### Claim 20 (depends on 1, 2)

The method of claim 1 or 2, wherein the marker and the biomarker are identical.

### Claim 21 (depends on 1, 2)

The method of claim 1 or 2, wherein the marker and the biomarker is an Fc receptor.

### Claim 22 (depends on 1, 2)

The method of claim 1 or 2, further comprising more than one marker.

### Claim 23 (depends on 1, 2)

The method of claim 1 or 2, wherein the kinetic model of biomarker expression during sperm capacitation comprises more than one biomarker.

### Claim 24 (depends on 1, 2)

The method of claim 1 or 2, wherein the kinetic model of biomarker expression during sperm capacitation comprises the biomarker Fc receptor.

### Claim 25 (depends on 1, 2)

The method of claim 1 or 2, wherein the kinetic model of biomarker expression during sperm capacitation is developed using ejaculates from the same species of said semen sample.

### Claim 26 (depends on 1, 2)

The method of claim 1 or 2, wherein said incubation of said semen sample comprises incubation at a temperature ranging from approximately 40 C to 4° C.

### Claim 27 (depends on 26)

The method of claim 26, wherein said incubation of said semen sample occurs at a temperature gradient ranging from approximately 40 C to 12° C.

### Claim 28 (depends on 2)

The method of claim 2, wherein said treatment decelerates the rate of capacitation.

### Claim 29 (depends on 2)

The method of claim 2, wherein said treatment accelerates the rate of capacitation.

### Claim 30 (depends on 2)

The method of claim 2, wherein said treatment arrests capacitation at a specific stage.

### Claim 31 (depends on 2)

The method of claim 2, wherein said treatment comprises exposing said semen sample to a chemical agent which modulates the rate of capacitation.

### Claim 32 (depends on 31)

The method of claim 31, wherein said agent is selected from the group consisting of endocannibinoids, bicarbonate and 8-butyryl cAMP.

### Claim 33 (depends on 2)

The method of claim 2, wherein said treatment comprises exposing said semen sample to an environmental stimulus which modulates the rate of capacitation.

### Claim 34 (depends on 33)

The method of claim 33, wherein said environmental stimulus is selected from the group consisting of barometric pressure, atmospheric pressure, temperature change and agitation.

### Claim 35 (depends on 33)

The method of claim 33, wherein said treatment comprises exposing said semen sample to an atmospheric condition which modulates the rate of capacitation.

### Claim 36 (depends on 35)

The method of claim 35, wherein said atmospheric condition comprises a gas which is selected from the group consisting of a nitric oxide, ozone, argon, cyanide and CO2.

### Claim 37 (depends on 36)

The method of claim 36, wherein said the CO2 concentration is greater than 5%.

### Claim 38 (depends on 1, 2)

The method of claim 1 or 2, wherein the marker or biomarker is expressed in the extracellular portion of said semen sample.

### Claim 39 (depends on 1, 2)

The method of claim 1 or 2, wherein the marker or biomarker is expressed by a sperm cell.

### Claim 40 (depends on 39)

The method of claim 39, wherein the marker or biomarker is expressed on the cell surface of said sperm cell.

### Claim 41 (depends on 39)

The method of claim 39, wherein the marker or biomarker is expressed in a membrane of the sperm cell.

### Claim 42 (depends on 41)

The method of claim 41, wherein the marker or biomarker is a change selected from the group consisting of membrane isotrophy, membrane fluidity, membrane charge, membrane permeability, membrane budding, membrane hydrophobicity, lipid raft structure, a lipid subdomain of the membrane, ion channel permeability, tyrosine phosphorylation, kinase activation, protease activation, kinase inactivation, protease inactivation, change in presence or amount of a ligand-binding molecule(s), and a calcium gradient.

### Claim 43 (depends on 39)

The method of claim 39, wherein the marker or biomarker is a lipid selected from the group of phosphatidyl serine, phosphatidlycholine, phosphatidyl ethanolamine and sphingomyelin.

### Claim 44 (depends on 39)

The method of claim 39, wherein the marker or biomarker further comprises its cellular location of the sperm.

### Claim 45 (depends on 39)

The method of claim 39, wherein the marker or biomarker is intracellularly expressed with respect to said sperm cell.

### Claim 46 (depends on 45)

The method of claim 45, wherein the intracellular marker or biomarker is selected from the group consisting of: intracellular pH, intracellular concentration of HCO3, intracellular concentration of fragmented DNA, mitochondrial Calcium and intracellular concentration of Calcium.

### Claim 47 (depends on 39)

The method of claim 39 where the marker or biomarker binds a glycoprotein or an anionic polysaccharide.

### Claim 48 (depends on 39)

The method of claim 39, where the marker or biomarker binds a glycosaminoglycan, a sulfated glycosaminoglycan, a sulfated glycan and a sulfated polylactosaminoglycans.

### Claim 49 (depends on 39)

The method of claim 39, where the marker or biomarker is selected from the group consisting of heparin, fucoidan, ZP3, a glycoprotein or fragment thereof derived from the egg vestments, and a Lewis antigen.

### Claim 50 (depends on 39)

The method of claim 39, where the marker or biomarker binds a dye.

### Claim 51 (depends on 39)

The method of claim 39, wherein the marker or biomarker is a physiologic activity selected from the group consisting of percent of sperm displaying motility, motility grade, frequency of beating of flagella of said sperm cell, ability of said sperm cell to penetrate mucus, loss of adhesion of said sperm cell, hypoosmotic swelling of said sperm cell, chemotaxis, thermotaxis and metabolic status of said sperm cell.

### Claim 52 (depends on 39)

The method of claim 39, where the marker or biomarker comprises a molecule secreted or expelled by said sperm cell.

### Claim 53 (depends on 38)

The method of claim 38, wherein the marker or biomarker comprises the appearance of exocytic vesicles or hybrid vesicles in solution.

### Claim 54 (depends on 52)

The method of claim 52, where in the secreted or expelled molecule is selected from the group consisting of an enzyme, a proenzyme, an agent, a reactive oxygen species, an exosomal vesicle, a dye and DNA fragments.

### Claim 55 (depends on 52)

The method of claim 52, where in the secreted or expelled agent is selected from the group consisting of an antibody bound fluorophore, a fluorophore and an enzyme.

### Claim 56 (depends on 1, 2)

The method of claim 1 or 2, wherein said biomarker is selected from the group consisting of Fertility-associated antigen, soybean trypsin inhibitor, an Fc receptor and CD46.

### Claim 57 (depends on 1, 2)

The method of claim 1 or 2, wherein said marker is selected from the group consisting of Fertility-associated antigen, soybean trypsin inhibitor, an Fc receptor and CD46.

### Claim 58 (depends on 9)

The method according to claim 9, wherein freezing said semen sample comprises adding a cryoprotectant selected from the group consisting of trehalose, glycerol, propylene glycol, dimethylsulfoxide, sucrose and egg yolk.

### Claim 59 (depends on 39)

The method of claim 39, where the marker or biomarker is permeability of said sperm to a dye.

### Claim 60 (depends on 59)

The method of claim 59, where the marker or biomarker is oscillatory behavior of said sperm in response to dye uptake and/or release.

### Claim 61 (depends on 49)

The method of claim 49, wherein the egg vestments of fragment thereof, is from the zona pellicida or fragments thereof.
